Anson Funds Management LP Rain Therapeutics Inc. Transaction History

Anson Funds Management LP

  • $839 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.84 - $1.22 $28,197 - $40,952
33,568 New
33,568 $40,000

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Anson Funds Management LP Portfolio

Follow Anson Funds Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Anson Funds Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email